FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057762070> ?p ?o ?g. }

• W2057762070 endingPage "3546" @default.
• W2057762070 startingPage "3540" @default.
• W2057762070 abstract "Abstract Objective Transforming growth factor β (TGFβ) and platelet‐derived growth factor (PDGF) may play a critical role in systemic sclerosis (SSc)–related interstitial lung disease (ILD), and imatinib is a potent inhibitor of TGFβ and PDGF production. In this 1‐year, phase I/IIa open‐label pilot study of imatinib in patients with SSc‐related active ILD, our primary aim was to assess the safety of imatinib; we also explored its efficacy. Methods We recruited 20 SSc patients with a forced vital capacity (FVC) of <85% predicted, dyspnea on exertion, and presence of a ground‐glass appearance on high‐resolution computed tomography. Patients received oral therapy with imatinib (up to 600 mg/day) for a period of 1 year. Adverse events were recorded, pulmonary function was tested, and the modified Rodnan skin thickness score (MRSS) was assessed every 3 months. The course of changes in lung function, the Health Assessment Questionnaire (HAQ) disability index (DI), and the MRSS were modeled over the period of study to explore treatment efficacy. Results The majority of patients were female (65%), Caucasian (75%), and had diffuse cutaneous SSc (70%). At baseline, the mean ± SD FVC % predicted was 65.2 ± 14.0 and the mean ± SD MRSS was 18.7 ± 10.1. The mean ± SD dosage of imatinib was 445 ± 125 mg/day. Of the 20 SSc patients, 12 completed the study, 7 discontinued because of adverse events (AEs), and 1 patient was lost to followup. Common AEs (≥20%) included fatigue, facial/lower extremity edema, nausea and vomiting, diarrhea, generalized rash, and new‐onset proteinuria. Treatment with imatinib showed a trend toward improvement in the FVC % predicted (1.74%; P not significant) and the MRSS (3.9 units; P < 0.001). Conclusion Use of high‐dose daily therapy with imatinib (600 mg/day) in SSc patients with ILD was associated with a large number of AEs. Our experience with AEs suggests that dosages of imatinib lower than 600 mg/day may be appropriate and that further dose ranging analysis is needed in order to understand the therapeutic index of imatinib in SSc." @default.
• W2057762070 created "2016-06-24" @default.
• W2057762070 creator A5002353467 @default.
• W2057762070 creator A5024950256 @default.
• W2057762070 creator A5026240805 @default.
• W2057762070 creator A5039783745 @default.
• W2057762070 creator A5056084449 @default.
• W2057762070 creator A5056836366 @default.
• W2057762070 creator A5059206584 @default.
• W2057762070 creator A5067493084 @default.
• W2057762070 creator A5073269240 @default.
• W2057762070 creator A5085290625 @default.
• W2057762070 date "2011-10-28" @default.
• W2057762070 modified "2023-10-16" @default.
• W2057762070 title "A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease" @default.
• W2057762070 cites W1965493606 @default.
• W2057762070 cites W1985004174 @default.
• W2057762070 cites W1990842725 @default.
• W2057762070 cites W2006874307 @default.
• W2057762070 cites W2009913945 @default.
• W2057762070 cites W2028921539 @default.
• W2057762070 cites W2029795839 @default.
• W2057762070 cites W2032383027 @default.
• W2057762070 cites W2052917153 @default.
• W2057762070 cites W2098471340 @default.
• W2057762070 cites W2108952847 @default.
• W2057762070 cites W2112302625 @default.
• W2057762070 cites W2125049108 @default.
• W2057762070 cites W2128764004 @default.
• W2057762070 cites W2131014787 @default.
• W2057762070 cites W2131369107 @default.
• W2057762070 cites W2145999911 @default.
• W2057762070 cites W2160470014 @default.
• W2057762070 cites W2166780351 @default.
• W2057762070 cites W4255779404 @default.
• W2057762070 doi "https://doi.org/10.1002/art.30548" @default.
• W2057762070 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3205223" @default.
• W2057762070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21769849" @default.
• W2057762070 hasPublicationYear "2011" @default.
• W2057762070 type Work @default.
• W2057762070 sameAs 2057762070 @default.
• W2057762070 citedByCount "125" @default.
• W2057762070 countsByYear W20577620702012 @default.
• W2057762070 countsByYear W20577620702013 @default.
• W2057762070 countsByYear W20577620702014 @default.
• W2057762070 countsByYear W20577620702015 @default.
• W2057762070 countsByYear W20577620702016 @default.
• W2057762070 countsByYear W20577620702017 @default.
• W2057762070 countsByYear W20577620702018 @default.
• W2057762070 countsByYear W20577620702019 @default.
• W2057762070 countsByYear W20577620702020 @default.
• W2057762070 countsByYear W20577620702021 @default.
• W2057762070 countsByYear W20577620702022 @default.
• W2057762070 countsByYear W20577620702023 @default.
• W2057762070 crossrefType "journal-article" @default.
• W2057762070 hasAuthorship W2057762070A5002353467 @default.
• W2057762070 hasAuthorship W2057762070A5024950256 @default.
• W2057762070 hasAuthorship W2057762070A5026240805 @default.
• W2057762070 hasAuthorship W2057762070A5039783745 @default.
• W2057762070 hasAuthorship W2057762070A5056084449 @default.
• W2057762070 hasAuthorship W2057762070A5056836366 @default.
• W2057762070 hasAuthorship W2057762070A5059206584 @default.
• W2057762070 hasAuthorship W2057762070A5067493084 @default.
• W2057762070 hasAuthorship W2057762070A5073269240 @default.
• W2057762070 hasAuthorship W2057762070A5085290625 @default.
• W2057762070 hasBestOaLocation W20577620702 @default.
• W2057762070 hasConcept C126322002 @default.
• W2057762070 hasConcept C141071460 @default.
• W2057762070 hasConcept C165637977 @default.
• W2057762070 hasConcept C197934379 @default.
• W2057762070 hasConcept C2777482430 @default.
• W2057762070 hasConcept C2777543607 @default.
• W2057762070 hasConcept C2777583451 @default.
• W2057762070 hasConcept C2777714996 @default.
• W2057762070 hasConcept C2778729363 @default.
• W2057762070 hasConcept C2780580376 @default.
• W2057762070 hasConcept C3018587741 @default.
• W2057762070 hasConcept C3019892230 @default.
• W2057762070 hasConcept C55520419 @default.
• W2057762070 hasConcept C71924100 @default.
• W2057762070 hasConcept C75603125 @default.
• W2057762070 hasConcept C90924648 @default.
• W2057762070 hasConceptScore W2057762070C126322002 @default.
• W2057762070 hasConceptScore W2057762070C141071460 @default.
• W2057762070 hasConceptScore W2057762070C165637977 @default.
• W2057762070 hasConceptScore W2057762070C197934379 @default.
• W2057762070 hasConceptScore W2057762070C2777482430 @default.
• W2057762070 hasConceptScore W2057762070C2777543607 @default.
• W2057762070 hasConceptScore W2057762070C2777583451 @default.
• W2057762070 hasConceptScore W2057762070C2777714996 @default.
• W2057762070 hasConceptScore W2057762070C2778729363 @default.
• W2057762070 hasConceptScore W2057762070C2780580376 @default.
• W2057762070 hasConceptScore W2057762070C3018587741 @default.
• W2057762070 hasConceptScore W2057762070C3019892230 @default.
• W2057762070 hasConceptScore W2057762070C55520419 @default.
• W2057762070 hasConceptScore W2057762070C71924100 @default.
• W2057762070 hasConceptScore W2057762070C75603125 @default.
• W2057762070 hasConceptScore W2057762070C90924648 @default.

• next